Abstract
The generation of autoantibodies and autoimmune diseases such as systemic lupus erythematosus has been associated with the use of certain drugs in humans. Early reports suggested that procainamide and hydralazine were associated with the highest risk of developing lupus, quinidine with a moderate risk and all other drugs were considered low or very low risk. More recently, drug-induced lupus has been associated with the use of the newer biological modulators such as tumour necrosis factor (TNF)-α inhibitors and interferons. The clinical features and laboratory findings of TNFα inhibitor-induced lupus are different from that of traditional drug-induced lupus or idiopathic lupus, and standardized criteria for the diagnosis of drug-induced lupus have not been established. The mechanism(s) responsible for the development of drug-induced lupus may vary depending on the drug or even on the patient. Besides lupus, other autoimmune diseases have been associated with drugs or toxins. Diagnosis of drug-induced lupus requires identification of a temporal relationship between drug administration and symptom development, and in traditional drug-induced lupus there must be no pre-existing lupus. Resolution of symptoms generally occurs after cessation of the drug.
In this review, we will discuss those drugs that are more commonly associated with drug-induced lupus, with an emphasis on the new biologicals and the difficulty of making the diagnosis of drug-induced lupus against a backdrop of the autoimmune diseases that these drugs are used to treat. Stimulation of the immune system by these drugs to cause autoimmunity may in fact be associated with an increased effectiveness in treating the pathology for which they are prescribed, leading to the dilemma of deciding which is worse, the original disease or the adverse effect of the drug. Optimistically, one must hope that ongoing research in drug development and in pharmacogenetics will help to treat patients with the maximum effectiveness while minimizing side effects. Vigilance and early diagnosis are critical. The purpose of this review is to summarize the most recent developments in our understanding of the incidence, pathogenesis, diagnosis and treatment of drug-induced lupus.
Similar content being viewed by others
References
Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann N Y Acad Sci 2007 Jun; 1108: 166–82
Chang C, Gershwin ME. Drugs and autoimmunity: a contemporary review and mechanistic approach. J Autoimmun 2010 May; 34(3): J266–75
Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 2010 May; 34(3): J258–65
Borchers AT, Naguwa SM, Shoenfeld Y, et al. The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 2010 Mar; 9(5): A277–87
Chang C. The immune effects of naturally occurring and synthetic nanoparticles. J Autoimmun 2010 May; 34(3): J234–46
Powell JJ, Faria N, Thomas-McKay E, et al. Origin and fate of dietary nanoparticles and microparticles in the gastrointestinal tract. J Autoimmun 2010 May; 34(3): J226–33
Selmi C, Tsuneyama K. Nutrition, geoepidemiology, and autoimmunity. Autoimmun Rev 2010 Mar; 9(5): A267–70
Tobon GJ, Youinou P, Saraux A. The environment, geoepidemiology, and autoimmune disease: rheumatoid arthritis. J Autoimmun 2010 Aug; 35(1): 10–4
Tomer Y. Hepatitis C and interferon induced thyroiditis. J Autoimmun 2010 May; 34(3): J322–6
Youinou P, Pers JO, Gershwin ME, et al. Geo-epidemiology and autoimmunity. J Autoimmun 2010 May; 34(3): J163–7
Hoffman BJ. Sensitivity to sulfadiazine resembling acute disseminated lupus erythematosus. Arch Dermatol Syphilol 1945; 51: 190–2
Sanford HS, Michaelson AK, Halpern MM. Procainamide induced lupus erythematosus syndrome. Dis Chest 1967 Feb; 51(2): 172–6
Reinhardt DJ, Waldron JM. Lupus erythematosus-like syndrome complicating hydralazine (apresoline) therapy. J Am Med Assoc 1954; 155: 1491–2
Yokoyama T, Usui T, Kiyama K, et al. Two cases of late-onset drug-induced lupus erythematosus caused by ticlopidine in elderly men. Mod Rheumatol 2010 Aug; 20(4): 405–9
Reich A, Bialynicki-Birula R, Szepietowski JC. Drug-induced subacute cutaneous lupus erythematosus resulting from ticlopidine. Int J Dermatol 2006 Sep; 45(9): 1112–4
Sontheimer RD, Henderson CL, Grau RH. Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation. Arch Dermatol Res 2009 Jan; 301(1): 65–70
Bonsmann G, Schiller M, Luger TA, et al. Terbinafine-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2001 Jun; 44(6): 925–31
Srivastava M, Rencic A, Diglio G, et al. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. Arch Dermatol 2003 Jan; 139(1): 45–9
Kluger N, Bessis D, Guillot B. Chronic cutaneous lupus flare induced by systemic 5-fluorouracil. J Dermatol Treatment 2006; 17: 51–3
Rubin RL. Drug-induced lupus. Toxicology 2005 Apr 15; 209(2): 135–47
Ladd AT. Procainamide-induced lupus erythematosus. N Engl J Med 1962; 267: 1357–8
Mongey AB, Donovan-Brand R, Thomas TJ, et al. Serologic evaluation of patients receiving procainamide. Arthritis Rheum 1992; 35: 1108–9
Morrow JD, Schroeder HA, Perry Jr HM. Studies on the control of hypertension by hyphex: II. toxic reactions and side effects. Circulation 1953 Dec; 8(6): 829–39
Yokogawa N, Vivino FB. Hydralazine-induced autoimmune disease: comparison to idiopathic lupus and ANCA-positive vasculitic. Mod Rheumatol 2009; 19: 338–47
Bernstein RM, Egerton-Vernon J, Webster J. Hydrallazine induced cutaneous vasculitis. BMJ 1980; 280: 156–7
Yokogawa N, Vivino FB. Hydralazine-induced autoimmune disease: comparison to idiopathic lupus and ANCA-positive vasculitis. Mod Rheumatol 2009; 19(3): 338–47
Mongey AB, Donovan-Brand R, Thomas TJ, et al. Serologic evaluation of patients receiving procainamide. Arthritis Rheum 1992 Feb; 35(2): 219–23
Rubin RL, Bell SA, Burlingame RW. Autoantibodies associated with lupus induced by diverse drugs target a similar epitope in the (H2A-H2B)-DNA complex. J Clin Invest 1992 Jul; 90(1): 165–73
Cohen MG, Kevat S, Prowse MV, et al. Two distinct quinidine-induced rheumatic syndromes. Ann Intern Med 1988 Mar; 108(3): 369–71
Eichenfield AH. Minocycline and autoimmunity. Curr Opin Pediatr 1999 Oct; 11(5): 447–56
Matsuura T, Shimizu Y, Fujimoto H, et al. Minocycline induced lupus. Lancet 1992; 340: 1553
Schlienger RG, Bircher AJ, Meier CR. Minocycline-induced lupus: a systematic review. Dermatology 2000; 200(3): 223–31
El-Hallak M, Giani T, Yaniay BS, et al. Chronic minocycline-induced lupus autoimmunity in children. J Pediatr 2008; 153: 303–4
Lawson TM, Amos N, Bulgen D, et al. Minocycline-induced lupus: clinical features and response to rechallenge. Rheumatology (Oxford) 2001 Mar; 40(3): 329–35
Dunphy J, Oliver M, Rands AL, et al. Antineutrophil cytoplasmic antibodies and HLA class II alleles in minocycline-induced lupus-like syndrome. Br J Dermatol 2000 Mar; 142(3): 461–7
Walshe JM. Penicillamine and the SLE syndrome. J Rheumatol Suppl 1981; 7: 155–60
Bray VJ, West SG, Schultz KT, et al. Antihistone antibody profile in sulfasalazine induced lupus. J Rheumatol 1994 Nov; 21(11): 2157–8
Gunnarsson I, Nordmark B, Hassan Bakri A, et al. Development of lupus-related side-effects in patients with early RA during sulphasalazine treatment-the role of IL-10 and HLA. Rheumatology (Oxford) 2000 Aug; 39(8): 886–93
Noel B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol 2007 Jan; 21(1): 17–24
Bonaci-Nikolic B, Nikolic MM, Andrejevic S, et al. Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs: comparison with idiopathic ANCA vasculitides. Arthritis Res Ther 2005; 7(5): R1072–81
Metcalf RG, Kuna A, Maccarron D. Disseminated lupus erythematosus versus drug reaction: report of a case receiving chlorpromazine. J Maine Med Assoc 1959 Jul; 50(7): 251–4
Canoso RT, de Oliveira RM. Chlorpromazine-induced anticardiolipin antibodies and lupus anticoagulant: absence of thrombosis. Am J Hematol 1988 Apr; 27(4): 272–5
Canoso RT, Sise HS. Chlorpromazine-induced lupus anticoagulant and associated immunologic abnormalities. Am J Hematol 1982 Sep; 13(2): 121–9
Laroche M, Borg S, Lassoued S, et al. Joint pain with aromatase inhibitors: abnormal frequency of Sjogren’s syndrome. J Rheumatol 2007 Nov; 34(11): 2259–63
Barendrecht MM, Tervaert JW, van Breda Vriesman PJ, et al. Susceptibility to cyclosporin A-induced auto-immunity: strain differences in relation to autoregulatory T cells. J Autoimmun 2002 Feb; 18(1): 39–48
Rao T, Richardson B. Environmentally induced autoimmune diseases: potential mechanisms. Environ Health Perspect 1999 Oct; 107 Suppl. 5: 737–42
Molina V, Shoenfeld Y. Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity 2005 May; 38(3): 235–45
Abedi-Valugerdi M. Mercury and silver induce B cell activation and anti-nucleolar autoantibody production in outbred mouse stocks: are environmental factors more important than the susceptibility genes in connection with autoimmunity? Clin Exp Immunol 2009 Jan; 155(1): 117–24
Rothschild B. Acrylamine-induced autoimmune phenomena. Clin Rheumatol 2010 Sep; 29(9): 999–1005
Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998 Sep; 41(9): 1552–63
Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993 Dec; 36(12): 1681–90
Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994 Oct 22; 344(8930): 1105–10
Charles PJ, Smeenk RJ, De Jong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000 Nov; 43(11): 2383–90
Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford) 2009 Jul; 48(7): 716–20
De Rycke L, Kruithof E, Van Damme N, et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003 Apr; 48(4): 1015–23
Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007 Jul; 86(4): 242–51
Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn’s disease: a prospective cohort study. Gastroenterology 2003 Jul; 125(1): 32–9
Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 2008 Jun; 37(6): 381–7
De Bandt M, Sibilia J, Le Loet X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005; 7(3): R545–51
Elkayam O, Burke M, Vardinon N, et al. Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab. Autoimmunity 2005 Mar; 38(2): 155–60
Jonsdottir T, Forslid J, van Vollenhoven A, et al. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis 2004 Sep; 63(9): 1075–8
De Rycke L, Baeten D, Kruithof E, et al. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 2005 Jul; 52(7): 2192–201
Eriksson C, Engstrand S, Sundqvist KG, et al. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 2005 Mar; 64(3): 403–7
Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005 Jul; 20(7): 1400–6
Mohan N, Edwards ET, Cupps TR, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol 2004 Oct; 31(10): 1955–8
Mor A, Bingham 3rd C, Barisoni L, et al. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol 2005 Apr; 32(4): 740–3
De Bandt M. Lessons for lupus from tumour necrosis factor blockade. Lupus 2006; 15(11): 762–7
Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991 Aug 1; 115(3): 178–83
Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006 Feb 16; 354(7): 709–18
Atkins MB, Mier JW, Parkinson DR, et al. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 1988 Jun 16; 318(24): 1557–63
Massarotti EM, Liu NY, Mier J, et al. Chronic inflammatory arthritis after treatment with high-dose interleukin-2 for malignancy. Am J Med 1992 Jun; 92(6): 693–7
Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol 2002 Aug; 2(4): 301–5
Uetrecht JP. Current trends in drug-induced autoimmunity. Toxicology 1997 Apr 11; 119(1): 37–43
Kretz-Rommel A, Duncan SR, Rubin RL. Autoimmunity caused by disruption of central T cell tolerance: a murine model of drug-induced lupus. J Clin Invest 1997 Apr 15; 99(8): 1888–96
Rubin RL, Kretz-Rommel A. Initiation of autoimmunity by a reactive metabolite of a lupus-inducing drug in the thymus. Environ Health Perspect 1999 Oct; 107 Suppl. 5: 803–6
Kretz-Rommel A, Rubin RL. Disruption of positive selection of thymocytes causes autoimmunity. Nat Med 2000 Mar; 6(3): 298–305
Ablin J, Verbovetski I, Trahtemberg U, et al. Quinidine and procainamide inhibit murine macrophage uptake of apoptotic and necrotic cells: a novel contributing mechanism of drug-induced-lupus. Apoptosis 2005 Oct; 10(5): 1009–18
Hieronymus T, Grotsch P, Blank N, et al. Chlorpromazine induces apoptosis in activated human lymphoblasts: a mechanism supporting the induction of drug-induced lupus erythematosus? Arthritis Rheum 2000 Sep; 43(9): 1994–2004
Balada E, Ordi-Ros J, Vilardell-Tarres M. DNA methylation and systemic lupus erythematosus. Ann N Y Acad Sci 2007 Jun; 1108: 127–36
Deng C, Lu Q, Zhang Z, et al. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum 2003 Mar; 48(3): 746–56
Gorelik G, Fang JY, Wu A, et al. Impaired T cell protein kinase C delta activation decreases ERK pathway signaling in idiopathic and hydralazine-induced lupus. J Immunol 2007 Oct 15; 179(8): 5553–63
Lu Q, Kaplan M, Ray D, et al. Demethylation of ITGAL (CD11a) regulatory sequences in systemic lupus erythematosus. Arthritis Rheum 2002 May; 46(5): 1282–91
Yung R, Powers D, Johnson K, et al. Mechanisms of drug-induced lupus: II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice. J Clin Invest 1996 Jun 15; 97(12): 2866–71
Oelke K, Richardson B. Decreased T cell ERK pathway signaling may contribute to the development of lupus through effects on DNA methylation and gene expression. Int Rev Immunol 2004 May–Aug; 23(3–4): 315–31
Zhou Y, Lu Q. DNA methylation in T cells from idiopathic lupus and drug-induced lupus patients. Autoimmun Rev 2008 May; 7(5): 376–83
Lu Q, Wu A, Richardson BC. Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J Immunol 2005 May 15; 174(10): 6212–9
Mevorach D. Systemic lupus erythematosus and apoptosis: a question of balance. Clin Rev Allergy Immunol 2003 Aug; 25(1): 49–60
Baima B, Sticherling M. Apoptosis in different cutaneous manifestations of lupus erythematosus. Br J Dermatol 2001 May; 144(5): 958–66
Blanco-Colio LM, Villa A, Ortego M, et al. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 2002 Mar; 161(1): 17–26
Hakamada-Taguchi R, Uehara Y, Kuribayashi K, et al. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res 2003 Nov 14; 93(10): 948–56
Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002 Nov 7; 420(6911): 78–84
Li J, Uetrecht JP. D-penicillamine-induced autoimmunity: relationship to macrophage activation. Chem Res Toxicol 2009 Sep; 22(9): 1526–33
Damoiseaux JG, Beijleveld LJ, van Breda Vriesman PJ. Multiple effects of cyclosporin A on the thymus in relation to T-cell development and autoimmunity. Clin Immunol Immunopathol 1997 Mar; 82(3): 197–202
Ferraccioli G, Mecchia F, Di Poi E, et al. Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis 2002 Apr; 61(4): 358–61
Wiik A. Drug-induced vasculitis. Curr Opin Rheumatol 2008 Jan; 20(1): 35–9
Acknowledgements
Financial support for the preparation of this review has been provided by the American Autoimmune Related Diseases Association. The authors have no conflicts of interest to declare that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chang, C., Gershwin, M.E. Drug-Induced Lupus Erythematosus. Drug-Safety 34, 357–374 (2011). https://doi.org/10.2165/11588500-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11588500-000000000-00000